PE-22-28: Mechanism, Evidence, and Dosing Protocols

Research disclaimer: PE-22-28 is sold for research purposes only and is not intended for human consumption. The information below is drawn from published scientific literature.

Evidence Tier

Animal studies only. Very early stage research. No human data of any kind. The mechanism is genuinely novel and the animal data is promising. The evidence base is the thinnest of any compound reviewed on this site.

PE-22-28 sits at the extreme frontier of the research peptide literature. Unlike even Dihexa (which has a more established research history), PE-22-28 has a very limited publication record. Researchers considering this compound are working with almost no human-relevant safety or efficacy data.

What Is PE-22-28?

PE-22-28 is a synthetic heptapeptide (Ser-Arg-Arg-His-Thr-Ser-Glu) designed as an optimised analog of spadin. Understanding PE-22-28 requires understanding the research context from which it emerged.

The lineage:

1. Spadin is a 17-amino acid peptide cleaved from the propeptide region of sortilin — a neurotensin receptor
2. Spadin was identified as a natural blocker of TREK-1 potassium channels in the brain
3. Spadin showed antidepressant effects in mice comparable to fluoxetine — but with faster onset and via a mechanistically novel pathway
4. PE-22-28 is an engineered fragment and analog of spadin, designed to preserve TREK-1 blocking activity in a shorter, more stable, and more potent molecule

The research group primarily responsible is Joëlle Chabry and colleagues at the Institut de Pharmacologie Moléculaire et Cellulaire (IPMC) in Sophia Antipolis, France.

Mechanism of Action

TREK-1 Channel Blockade (Primary)

TREK-1 (TWIK-related potassium channel 1) is a two-pore domain K+ channel expressed in brain regions involved in mood regulation — particularly the hippocampus, amygdala, and prefrontal cortex. TREK-1 channels stabilise neuronal resting membrane potential and reduce neuronal excitability.

TREK-1 knockout mice (mice genetically engineered to lack TREK-1) are resistant to depression in animal models — stress-induced helplessness, tail suspension, and forced swim tests all show antidepressant-like behaviour in TREK-1-null animals. This established TREK-1 as a target for antidepressant development.

PE-22-28 blocks TREK-1, pharmacologically mimicking the TREK-1 knockout phenotype. Blocking this “braking” channel increases neuronal excitability in the affected circuits — with the downstream effect of increased serotonin neurotransmission (through improved serotonergic raphe neuron firing), increased BDNF release, and enhanced hippocampal neurogenesis.

This mechanism is entirely distinct from all current antidepressants:

• SSRIs block serotonin reuptake transporters
• SNRIs block serotonin + norepinephrine reuptake
• MAOIs block monoamine oxidase
• Ketamine blocks NMDA receptors
• PE-22-28/spadin blocks TREK-1 K+ channels

Rapid BDNF Release

A key pharmacodynamic feature: spadin and PE-22-28 produce BDNF release rapidly — within hours of administration rather than weeks. Conventional antidepressants require 2–4 weeks for clinical effect, in part because their downstream neuroplastic effects (including BDNF upregulation) develop slowly. The TREK-1 mechanism appears to produce faster BDNF effects, which may explain the rapid antidepressant response seen in animal models.

This connects PE-22-28 to the growing interest in rapid-onset antidepressants (ketamine being the clinical example) — compounds that produce measurable antidepressant effects within days rather than weeks.

Hippocampal Neurogenesis

Beyond the acute effects, spadin and PE-22-28 promote hippocampal neurogenesis — the growth of new neurons in the dentate gyrus. Impaired neurogenesis is consistently observed in depression models and is restored by effective antidepressant treatment. PE-22-28 appears to produce this neurogenic effect more rapidly than SSRIs in animal models.

Serotonergic Upregulation

Downstream of TREK-1 blockade, serotonin neurotransmission is enhanced — not by blocking reuptake but by increasing serotonergic neuron firing rate. The net result in terms of synaptic serotonin is similar to SSRIs, but the mechanism is upstream. Whether this produces fewer of the side effects associated with reuptake blockade (sexual dysfunction, GI effects) is unstudied in humans.

What the Evidence Actually Shows

Antidepressant Effect in Animal Models

Spadin and PE-22-28 show antidepressant-like behaviour in standard rodent models: forced swim test, tail suspension, sucrose preference (anhedonia model), and chronic mild stress models. The effect size is comparable to fluoxetine in these assays.

The onset appears faster than fluoxetine in rodent studies — measurable effect within 3–4 days versus 2–3 weeks for fluoxetine in the same models.

Neuroplasticity Markers

Post-mortem analysis of treated animals shows: increased dendritic branching in hippocampal neurons, increased BDNF protein levels, and increased newborn neuron density in the dentate gyrus. These are the structural correlates of the antidepressant behaviour.

PE-22-28 vs Spadin

PE-22-28 was specifically designed to be more potent and more stable than spadin. In cell electrophysiology assays, PE-22-28 blocks TREK-1 channels at lower concentrations than spadin. In animal behavioural assays, PE-22-28 shows comparable or superior antidepressant effects to spadin at lower doses. The engineering appears to have succeeded in improving the pharmacology.

What Is Not Established

• All human data — entirely absent
• Safety in humans at any dose
• Whether TREK-1 blockade produces the expected serotonergic effect in humans (channel kinetics differ between species)
• Optimal dose, route, and frequency
• Duration of effect with repeated dosing
• Whether neurogenesis-promoting effects occur at all in adult human brains (human adult hippocampal neurogenesis is itself a controversial area)
• Interaction with existing psychiatric medications
• Long-term safety — TREK-1 is expressed in the heart and other peripheral tissues; implications of chronic TREK-1 blockade beyond the CNS are unknown

Dosing Protocols (Research Context)

No human dose exists. All protocols are animal-extrapolated.

For a 70 kg human: rough allometric equivalent would be approximately 5–28 mg. Actual effective human dose — if it translates at all — is completely unknown.

Reconstitution: Dissolve in bacteriostatic water. PE-22-28 should be water-soluble given its amino acid composition (polar residues). Confirm solubility with specific supplier preparation.

Storage: Lyophilised: −20°C. Reconstituted: refrigerate 2–8°C, use within 30 days.

The Honest Assessment

PE-22-28 is scientifically interesting for two reasons: the mechanism (TREK-1 blockade) is genuinely novel and distinct from all existing psychiatric pharmacology, and the rapid neuroplastic effects in animal models — if they translate — would address the major limitation of conventional antidepressants (slow onset).

But the evidence is thin. Very few papers. One research group doing most of the work. No human data of any kind. A novel mechanism is not, by itself, evidence of safety or efficacy in humans — the history of psychiatry is full of mechanistically novel compounds that failed in translation.

PE-22-28 is a compound to monitor closely as the literature develops. It is not one to deploy on the basis of current evidence.

Summary

PE-22-28 targets TREK-1 potassium channel blockade — a mechanism unlike any approved drug — and produces rapid antidepressant and neurogenic effects in animal models. The biology is interesting and the mechanism is well-characterised at the molecular level. The human evidence is nonexistent. The appropriate posture is scientific interest and watchfulness, not deployment. If this compound ever reaches human trials, that data will fundamentally change the risk calculus. Until then, the honest position is that we do not know.

See also: PE-22-28 data page